When the options market explodes with call buying in a stock it is a pretty good sign something is on the way. In the NASDAQ:ARQL options market the $10 call strike expiry July 19th have seen up to 400% higher volume than normal. That is significant as earnings are not due until August, so there must be another stimulus on the way. Keep on the watchlist.
AVERAGE ANALYSTS PRICE TARGET $8.54
AVERAGE RECOMMENDATION BUY
SHORT INTEREST 8.7%
COMPANY PROFILE
ArQule, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutics to treat cancers and rare diseases. The company discovers, develops and commercializes novel small molecule drugs in areas of unmet need that will dramatically extend and improve the lives of its patients. Its proprietary pipeline includes ARQ 531, Derazantinib, Miransertib, ARQ 751 and Derazantinib products.
AVERAGE ANALYSTS PRICE TARGET $8.54
AVERAGE RECOMMENDATION BUY
SHORT INTEREST 8.7%
COMPANY PROFILE
ArQule, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutics to treat cancers and rare diseases. The company discovers, develops and commercializes novel small molecule drugs in areas of unmet need that will dramatically extend and improve the lives of its patients. Its proprietary pipeline includes ARQ 531, Derazantinib, Miransertib, ARQ 751 and Derazantinib products.